{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:58Z","timestamp":1792001938813,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T00:00:00Z","timestamp":1297123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1038\/sj.bjc.6606092","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T16:01:46Z","timestamp":1297180906000},"page":"863-870","source":"Crossref","is-referenced-by-count":282,"title":["HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm"],"prefix":"10.1038","volume":"104","author":[{"given":"T","family":"Van Gorp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Cadron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Despierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Leunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Amant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"De Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,8]]},"reference":[{"key":"BF6606092_CR1","unstructured":"HE4 EIA product insert, version 2008-09. Available from URL: http:\/\/www.fdi.com\/documents\/products\/inserts\/eia\/HE4%20EIA%20404-10,%202008-09,%20r1.pdf (accessed 1 April 2010)"},{"key":"BF6606092_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ygyno.2009.10.087","volume":"116","author":"MR Andersen","year":"2010","unstructured":"Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban N (2010) Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 116: 378\u2013383","journal-title":"Gynecol Oncol"},{"key":"BF6606092_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJM198310133091503","volume":"309","author":"RC Bast Jr","year":"1983","unstructured":"Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski Jr VR, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883\u2013887","journal-title":"N Engl J Med"},{"key":"BF6606092_CR4","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1038\/sj.onc.1205363","volume":"21","author":"L Bingle","year":"2002","unstructured":"Bingle L, Singleton V, Bingle CD (2002) The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 21: 2768\u20132773","journal-title":"Oncogene"},{"key":"BF6606092_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0002-9378(96)70381-2","volume":"174","author":"GG Bon","year":"1996","unstructured":"Bon GG, Kenemans P, Verstraeten R, van Kamp GJ, Hilgers J (1996) Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 174: 107\u2013114","journal-title":"Am J Obstet Gynecol"},{"key":"BF6606092_CR6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/clinchem\/43.3.491","volume":"43","author":"JM Bonfrer","year":"1997","unstructured":"Bonfrer JM, Korse CM, Verstraeten RA, van Kamp GJ, Hart GA, Kenemans P (1997) Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value. Clin Chem 43: 491\u2013497","journal-title":"Clin Chem"},{"key":"BF6606092_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1470-2045(06)70579-4","volume":"7","author":"D Bouchard","year":"2006","unstructured":"Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM (2006) Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 7: 167\u2013174","journal-title":"Lancet Oncol"},{"key":"BF6606092_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837\u2013845","journal-title":"Biometrics"},{"key":"BF6606092_CR9","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65: 2162\u20132169","journal-title":"Cancer Res"},{"key":"BF6606092_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ygyno.2008.09.036","volume":"112","author":"A du Bois","year":"2009","unstructured":"du Bois A, Rochon J, Pfisterer J, Hoskins WJ (2009) Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 112: 422\u2013436","journal-title":"Gynecol Oncol"},{"key":"BF6606092_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/modpathol.3800612","volume":"19","author":"MT Galgano","year":"2006","unstructured":"Galgano MT, Hampton GM, Frierson Jr HF (2006) Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19: 847\u2013853","journal-title":"Mod Pathol"},{"key":"BF6606092_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ygyno.2004.11.039","volume":"96","author":"CB Gilks","year":"2005","unstructured":"Gilks CB, Vanderhyden BC, Zhu S, van de RM, Longacre TA (2005) Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96: 684\u2013694","journal-title":"Gynecol Oncol"},{"key":"BF6606092_CR13","first-page":"3695","volume":"63","author":"I Hellstrom","year":"2003","unstructured":"Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63: 3695\u20133700","journal-title":"Cancer Res"},{"key":"BF6606092_CR14","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","volume":"100","author":"K Huhtinen","year":"2009","unstructured":"Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setala M, Harkki P, Jalkanen J, Fraser J, Makinen J, Auranen A, Poutanen M, Perheentupa A (2009) Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 100: 1315\u20131319","journal-title":"Br J Cancer"},{"key":"BF6606092_CR15","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1158\/1078-0432.CCR-03-0409","volume":"10","author":"KH Lu","year":"2004","unstructured":"Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast Jr RC (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291\u20133300","journal-title":"Clin Cancer Res"},{"key":"BF6606092_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/jcla.20340","volume":"23","author":"M Montagnana","year":"2009","unstructured":"Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, Salvagno GL, Giudici S, Franchi M, Guidi GC (2009) The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 23: 331\u2013335","journal-title":"J Clin Lab Anal"},{"key":"BF6606092_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","volume":"110","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC, Lu K (2008a) Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110: 196\u2013201","journal-title":"Gynecol Oncol"},{"key":"BF6606092_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC (2008b) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108: 402\u2013408","journal-title":"Gynecol Oncol"},{"key":"BF6606092_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ajog.2010.03.043","volume":"203","author":"RG Moore","year":"2010","unstructured":"Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ (2010) Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 203: 228. e1\u2013228.e6","journal-title":"Am J Obstet Gynecol"},{"key":"BF6606092_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","volume":"112","author":"RG Moore","year":"2009","unstructured":"Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112: 40\u201346","journal-title":"Gynecol Oncol"},{"key":"BF6606092_CR21","doi-asserted-by":"publisher","first-page":"e2633","DOI":"10.1371\/journal.pone.0002633","volume":"3","author":"C Palmer","year":"2008","unstructured":"Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N (2008) Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 3: e2633","journal-title":"PLoS One"},{"key":"BF6606092_CR22","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-05-2007","volume":"12","author":"N Scholler","year":"2006","unstructured":"Scholler N, Crawford M, Sato A, Drescher CW, O\u2032Briant KC, Kiviat N, Anderson GL, Urban N (2006) Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 12: 2117\u20132124","journal-title":"Clin Cancer Res"},{"key":"BF6606092_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0378-1119(99)00342-X","volume":"238","author":"M Schummer","year":"1999","unstructured":"Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L (1999) Comparative hybridization of an array of 21\u2009500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238: 375\u2013385","journal-title":"Gene"},{"key":"BF6606092_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/uog.6443","volume":"34","author":"C Van Holsbeke","year":"2009","unstructured":"Van Holsbeke C, Daemen A, Yazbek J, Holland TK, Bourne T, Mesens T, Lannoo L, De Moor B, De Jonge E, Testa AC, Valentin L, Jurkovic D, Timmerman D (2009) Ultrasound methods to distinguish between malignant and benign adnexal masses in the hands of examiners with different levels of experience. Ultrasound Obstet Gynecol 34: 454\u2013461","journal-title":"Ultrasound Obstet Gynecol"},{"key":"BF6606092_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0090-8258(88)90039-X","volume":"30","author":"VR Zurawski Jr","year":"1988","unstructured":"Zurawski Jr VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast Jr RC, Ritts Jr RE, Malkasian G (1988) An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 30: 7\u201314","journal-title":"Gynecol Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6606092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6606092","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6606092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:49:12Z","timestamp":1684399752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6606092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,8]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["BF6606092"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6606092","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,8]]}}}